Emphysema Market Report 2026

Emphysema Market Overview

• Emphysema market size has reached to $4.94 billion in 2025 • Expected to grow to $6.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.6% • Growth Driver: Rise In Respiratory Infections Driving The Growth Of The Market Due To Increasing Disease Progression • Market Trend: Advancements In Inhaled Therapy For Chronic Obstructive Pulmonary Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Emphysema Market?

Emphysema is a chronic lung disease that damages the air sacs (alveoli) in the lungs, leading to difficulty in breathing. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by smoking or long-term exposure to air pollutants. As the alveoli become weakened and lose their elasticity, air gets trapped, making it harder for the lungs to expel carbon dioxide and take in fresh oxygen. This results in shortness of breath, chronic cough, and reduced lung function over time. The main types of emphysema are centrilobular and panlobular. Centrilobular refers to the central region of a liver or lung lobule, often associated with conditions like centrilobular emphysema in the lungs or centrilobular necrosis in the liver. Treatment options for emphysema include medication, therapy, surgery, and other treatments. Diagnosis typically involves imaging tests, lung function tests, and other diagnostics. Common complications of emphysema include chest infections, collapsed lung, heart problems, lung holes, and other related issues. It is commonly treated in hospitals and clinics, surgical centers, and others.

What Is The Emphysema Market Growth Forecast?

The emphysema market size is expected to see steady growth in the next few years. It will grow to $6.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to early screening initiatives, home-based respiratory care, advanced diagnostic adoption, chronic disease management focus, environmental health regulations. Major trends in the forecast period include rising prevalence of chronic respiratory diseases, increased focus on early diagnosis of copd, growth in long-term oxygen therapy, expansion of pulmonary rehabilitation programs, emphasis on smoking cessation interventions.

Global Emphysema Market Segmentation

1) By Type: Centrilobular, Panlobular 2) By Treatment: Medication, Therapy, Surgery, Other Treatments 3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis 4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications 5) By End-User: Hospitals And Clinics, Surgical Center, Other End-Users Subsegments: 1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema 2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

What Is The Driver Of The Emphysema Market?

The increasing prevalence of respiratory infections is expected to propel the growth of the emphysema market going forward. Respiratory infections refer to infections that affect the respiratory system, including the sinuses, throat, airways, and lungs. Growing respiratory infections are due to pollution, climate change, antimicrobial resistance, urbanization, and evolving pathogens. Respiratory infections accelerate emphysema progression by causing inflammation, tissue damage, and increased airway obstruction, worsening lung function. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, the U.S. reported 9,633 tuberculosis (TB) cases, a 15.6% rise from 8,332 in 2022, with the incidence rate increasing 15.0% from 2.5 to 2.9 per 100,000 persons. Therefore, the increasing prevalence of respiratory infections is driving the growth of the emphysema industry.

Key Players In The Global Emphysema Market

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann‑La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

Global Emphysema Market Trends and Insights

Major companies operating in the emphysema market are focusing on medical innovations, such as inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4, to provide patients with advanced treatments that improve lung function, reduce inflammation, and enhance overall management of the disease, fostering better respiratory health and quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 is a medication that targets and blocks both phosphodiesterase enzymes in the lungs, which helps relax the airways and reduce inflammation, improving breathing in conditions like chronic obstructive pulmonary disease. For instance, in June 2024, Verona Pharma plc, a UK-based pharma company, launched Ohtuvayre (ensifentrine), the first inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a US-based federal agency, for the maintenance treatment of chronic obstructive pulmonary diseases like emphysema, marking the first novel inhaled therapy in over 20 years. The drug, which combines bronchodilator and anti-inflammatory effects, is to be available through specialty pharmacies.

What Are Latest Mergers And Acquisitions In The Emphysema Market?

In October 2023, Aileron Therapeutics Inc., a US-based biopharmaceutical company, acquired Lung Therapeutics for an undisclosed amount. With this acquisition, Aileron Therapeutics aims to expand its pipeline by acquiring Lung Therapeutics, gaining access to multiple clinical-stage therapies, including LTI-03, a novel Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis, to address life-threatening lung conditions that have limited or no approved treatments. Lung Therapeutics is a US-based pharmaceutical company that developed treatments for lung diseases and injuries such as emphysema.

Regional Outlook

North America was the largest region in the emphysema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Emphysema Market?

The emphysema market consists of revenues earned by entities by providing services such as diagnosis and screening services, oxygen therapy, pulmonary rehabilitation programs, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The emphysema market also includes sales of bronchodilators, corticosteroids, oxygen therapy devices, nebulizers, and pulmonary rehabilitation products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Emphysema Market Report 2026?

The emphysema market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the emphysema industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.